

November 2009

Interested in improving contraceptive research?

How about an additional \$1,000 around the holidays? The Women's Health Research Unit at OHSU is currently conducting a study assessing the effect of Celecoxib 400 mg (Celebrex®) on ovulation. The goal of this clinical trial is to assess whether Celebrex may be used as an alternative form of emergency contraception or to manage fertility. Celebrex is currently approved by the U.S. Food & Drug Administration (FDA) to treat primary dysmenorrhea (cramping and painful menstruation) and arthritis symptoms. The study consists of numerous visits over 5 complete menstrual cycles (approximately 5 months). **Participants may be compensated up to \$1,000 for time and costs related to the study.** Participants will receive study drug/ placebo and study related exams at no cost and will undergo vaginal ultrasounds and blood draws twice a week. To qualify, participants should not be at risk for pregnancy or should be willing to use a non-hormonal form of contraception throughout the study duration.

Call to learn more

If you would like to learn more about this research study or have questions please call the Women's Health Research Unit's confidential line at **503 494-3666**.

Sincerely,

Heidi Printz, Ph.D.
Research Administrator
Department of Obstetrics and Gynecology

The Women's Health Research Unit at OHSU: Finding New Solutions to Old Problems.